What a dispensed drug label has to carry

There are two labels, and people argue about the wrong one

A prescription drug that reaches a person usually carries two layers of labeling, written by two different parties under two different rules.

One is the label the maker puts on the package. The other is the label the dispenser applies when it fills a specific order for a specific person.

Most arguments about peptide packaging are really about the first layer, because that is the one a product photograph shows. The second layer is the one that tells you who handled your order.

They are worth separating, because a vial can be beautifully printed and still arrive with nothing identifying the pharmacy, the prescriber or you.

The dispensed label is five short items

Federal law gives a dispensed prescription an exemption from most of the misbranding rules, and it buys that exemption with a list.

The label has to bear the name and address of the dispenser. It has to bear the serial number and date of the prescription or of its filling, and the name of the prescriber. It has to bear the name of the patient, if the prescription stated it. And it has to bear the directions for use and any cautionary statements the prescription contained.

Notice which item is conditional. The patient name appears only if the prescription stated it. Everything else on that list is unconditional.

Notice also what the first item does. A dispensed label names the dispenser by name and address, which means the question "who filled this" is supposed to be answered on the box rather than in a support ticket.

The same statute adds a separate, blunter rule. A drug in this category is deemed misbranded if, at any time before dispensing, its label fails to bear at a minimum the symbol "Rx only".

The clause about mail that nobody quotes

The exemption above carries a sentence that reads oddly in a market built on remote intake forms.

It says the exemption does not apply to a drug dispensed in the course of the conduct of a business of dispensing drugs pursuant to diagnosis by mail.

That language is old, it predates the internet, and how it reaches any modern arrangement is a question for regulators and courts rather than for a comparison site. This article states that the words exist and stops there.

It is quoted here for one reason only. A reader who goes looking at the statute will find it, and it is better to meet it with context than to discover it as a gotcha.

The manufacturer-side list, and the line about lot numbers

The other layer sits in the labeling regulations, which set out what a prescription drug package must bear to qualify for its own exemption.

The list runs to seven items. The statement "Rx only". The recommended or usual dosage. The route of administration, if the product is not for oral use. The quantity or proportion of each active ingredient.

For anything not taken by mouth, the names of all inactive ingredients. For anything intended for injection, the rule goes further and asks for the quantity or proportion of all inactive ingredients, with narrow allowances for pH adjusters and for water used as a vehicle.

Then the item worth pausing on: an identifying lot or control number from which it is possible to determine the complete manufacturing history of the package of the drug.

That is a demanding sentence. The number is not a decoration or a batch nickname. It is meant to be an index that leads back to a complete manufacturing history held by whoever made the package.

The seventh item is a statement directed to the pharmacist specifying the type of container to use, so the product keeps its identity, strength, quality and purity while it sits on a shelf.

What an outsourcing facility has to print, item by item

The compounding law splits into two sections, and only one of them contains a label list. That one covers outsourcing facilities.

Its list is long and unusually specific. The label must say "This is a compounded drug" or a comparable statement that prominently identifies it as one. It must carry the name, address and phone number of the facility.

It must then carry the lot or batch number, the established name of the drug, the dosage form and strength, and the statement of quantity or volume. It must carry the date the drug was compounded, the expiration date, and storage and handling instructions. It must also carry a list of active and inactive ingredients, with the quantity or proportion of each.

Two of its items are quietly informative. One requires the phrase "Not for resale". The other requires the national drug code number, and the statute qualifies it with the words "if available", which is the law conceding that a compounded preparation may not have one.

There is one more requirement, on the container rather than the vial. It has to carry the address and phone number of the federal adverse event reporting program, so a person who has a problem can find where to report it.

The section that governs pharmacies prints no list at all

The companion section, the one that covers compounding by a pharmacist or physician for an identified individual patient, is different in a way that surprises people.

It exempts a qualifying preparation from certain requirements, including the requirement to bear adequate directions for use and the requirement to go through drug approval. What it does not do is set out label contents.

A search of that section for the word "label" returns two hits, and both of them sit inside its definition of compounding, where the phrase refers to a manufacturer's approved labeling. The same search over the outsourcing facility section returns the list quoted above.

That is a statement about one federal section, not a conclusion that such a preparation may arrive unlabeled. The dispensing rule further up this page is a separate provision, and state pharmacy law adds requirements this site has not surveyed state by state.

The practical point stands anyway. The detailed federal label list attaches to one category of compounder and not the other, so which category filled your order changes what the printed rules already require of the box.

The vial that carries none of this

A vial sold with a research-use-only label sits outside every rule above rather than at the edge of them.

There is no dispenser to name, because nothing was dispensed against a prescription. There is no serial number, no prescriber and no patient name, because there was no prescription to number.

What such a vial usually carries instead is a product name, a quantity and a disclaimer. Those are not the same category of information, and a certificate supplied alongside does not convert the transaction into a dispensing.

This is the fastest way to tell the two markets apart without reading a single marketing page. Look at what the box is required to say, then look at what it says.

Reading your own box

None of this tells you whether a given order was handled properly. It tells you which observations are worth making.

Is a dispenser named, with an address? Is there a prescription number and a date? Is a prescriber named? Are there directions and any cautionary statements the prescription carried?

If the product is a compounded preparation from an outsourcing facility, does it say so in words, and does it carry a lot or batch number, a compounding date and an expiration date?

And if the answer to most of these is no, that is not automatically a violation of anything. It is a strong signal about which of the two markets you are actually buying in.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. United States Code Title 21, Section 353(b), Exemptions and consideration for certain drugs, devices, and biological products, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
2. United States Code Title 21, Section 353a, Pharmacy compounding, read in full and searched for label content requirements, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
3. United States Code Title 21, Section 353b(a)(10), Outsourcing facilities, labeling of drugs, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
4. Title 21 Code of Federal Regulations section 201.100, Prescription drugs for human use — Electronic Code of Federal Regulations, Office of the Federal Register, January 2006